The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma

被引：0
|
作者：
Borellini, F. [1 ]
机构：
[1] Roche, Global Prod Strategy, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70545-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [31] Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma
    Kim, Hee Kyung
    Lee, Sunyoung
    Kim, Kyung
    Heo, Mi Hwa
    Lee, Hansang
    Cho, Jinhyun
    Kim, Nayoung K. D.
    Park, Woongyang
    Lee, Su Jin
    Kim, Jung Han
    Jang, Kee-Taek
    Choi, Sang-Hee
    Lee, Jeeyun
    [J]. TRANSLATIONAL ONCOLOGY, 2016, 9 (06): : 557 - 564
  • [32] Therapeutic Reality of Patients with BRAF-mutated advanced/metastatic Melanoma in Germany and Austria
    Haferkamp, S.
    Alter, M.
    Debus, D.
    Schilling, B.
    Pinter, A.
    Terheyden, P.
    Utikal, J.
    Sachse, M. M.
    Haalck, T.
    Wolf, I.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 71 - 72
  • [33] Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma
    Kiniwa, Yukiko
    Okuyama, Ryuhei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 315 - 320
  • [34] The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
    Liu, Xiao
    Wu, Jinfeng
    Qin, Haihong
    Xu, Jinhua
    [J]. TARGETED ONCOLOGY, 2018, 13 (04) : 437 - 446
  • [35] Treatment of BRAF-mutated advanced cutaneous melanoma
    Van Anh Trinh
    You, Yan
    Hwu, Wen-Jen
    [J]. CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
  • [36] Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma
    Kim, Jenna May
    Weiss, Sarah
    Sinard, John H.
    Pointdujour-Lim, Renelle
    [J]. OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (01) : 35 - 38
  • [37] Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
    Karolina Piejko
    Bożena Cybulska-Stopa
    Marcin Ziętek
    Robert Dziura
    Łukasz Galus
    Natasza Kempa-Kamińska
    Barbara Ziółkowska
    Ewa Rutkowska
    Tomasz Kopciński
    Tomasz Kubiatowski
    Wiesław Bal
    Rafał Suwiński
    Jacek Mackiewicz
    Grażyna Kamińska-Winciorek
    Anna M. Czarnecka
    Piotr Rutkowski
    [J]. Targeted Oncology, 2023, 18 : 235 - 245
  • [38] Adjuvant Therapy with Nivolumab in BRAF-mutated Melanoma
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [39] The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
    Xiao Liu
    Jinfeng Wu
    Haihong Qin
    Jinhua Xu
    [J]. Targeted Oncology, 2018, 13 : 437 - 446
  • [40] Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan
    Silkin S.V.
    Startsev S.S.
    Krasnova M.E.
    Raskin G.A.
    Mitiushkina N.V.
    Iyevleva A.G.
    Sokolenko A.P.
    Imyanitov E.N.
    [J]. Journal of Gastrointestinal Cancer, 2016, 47 (4) : 502 - 505
12345